2023
Phase II trial of pembrolizumab in patients with brain metastases.
Brastianos P, Kim A, Giobbie-Hurder A, Lee E, Lin N, Overmoyer B, Wen P, Nayak L, Cohen J, Dietrich J, Heist R, Krop I, Lawrence D, Mayer E, Winer E, Shih H, Oh K, Cahill D, Gerstner E, Sullivan R. Phase II trial of pembrolizumab in patients with brain metastases. Journal Of Clinical Oncology 2023, 41: 2006-2006. DOI: 10.1200/jco.2023.41.16_suppl.2006.Peer-Reviewed Original ResearchBrain metastasesPrimary endpointBenefit rateEvaluable patientsLung cancerBreast cancerTherapeutic strategiesSingle-arm phase 2 clinical trialNon-small cell lung cancerHormone receptor-positive diseaseSmall cell lung cancerPhase 2 clinical trialGrade 4 toxicityLogical therapeutic strategyRECIST 1.1 criteriaMedian overall survivalPD-1 blockadePD-1 inhibitorsPrimary efficacy endpointReceptor-positive diseasePhase II trialImmune-based strategiesTriple-negative subtypeCell lung cancerT cell cytotoxicity
2009
A phase I study of an autologous GM-CSF-secreting breast cancer vaccine.
Anderson K, Hodi F, Sasada T, Canning C, Hassett M, Mayer E, Hannagan K, Wong J, Colson Y, Shoji B, Najita J, Sibani S, LaBaer J, Winer E, Dranoff G. A phase I study of an autologous GM-CSF-secreting breast cancer vaccine. Cancer Research 2009, 69: 4124. DOI: 10.1158/0008-5472.sabcs-4124.Peer-Reviewed Original ResearchBreast cancer vaccinesGM-CSFAutologous GM-CSFCancer vaccinesLung cancerSkin biopsiesImmune responseECOG performance status 0Antigen-specific immune responsesLocal injection site reactionsPerformance status 0Anti-tumor immunityInjection site reactionsMetastatic breast cancerMalignant pleural effusionReplication-defective adenoviral vectorMultiple tumor modelsGM-CSF secretionBreast cancer cellsTumor cell yieldGranulocyte-macrophage colonyAutologous vaccinationMeasurable diseasePrior chemotherapyStable disease
2007
Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS. Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. Journal Of Clinical Oncology 2007, 26: 313-325. PMID: 18086794, DOI: 10.1200/jco.2007.15.4088.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteClinical Trials Cooperative GroupsClinical OncologyCancer researchAmerican SocietyCancer treatmentScreening—A ReportHormone replacement therapyBreast cancer incidenceNumber of patientsBreast cancer screeningClinical cancer researchReplacement therapyCancer research fundingHuman papillomavirusCancer careCancer patientsCancer screeningLung cancerNeck cancerCancer incidenceClinical trialsKidney cancerLiver cancerRadiation therapyInvasive breast cancer.
Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. Journal Of The National Comprehensive Cancer Network 2007, 5: 246-312. PMID: 17439758, DOI: 10.6004/jnccn.2007.0025.Peer-Reviewed Original ResearchConceptsInvasive breast cancerBreast cancerBreast cancer mortalityAmerican Cancer SocietyMore effective treatmentsCommon malignancyCancer mortalityCancer deathLung cancerCancer SocietyEffective treatmentNew casesCancerEarly detectionUnited StatesTreatmentGuidelinesMalignancyMortalityIncidenceDiseaseDiagnosisWomen
2005
Breast cancer.
Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Breast cancer. Journal Of The National Comprehensive Cancer Network 2005, 3: 238-89. PMID: 16002000, DOI: 10.6004/jnccn.2005.0015.Peer-Reviewed Original Research
1997
796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support
Crawford J, Blackwell S, Shoemaker D, Pupa M, Mulhausen T, Herndon J, Winer E, Flynn J, Dempsey H. 796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support. Lung Cancer 1997, 18: 205. DOI: 10.1016/s0169-5002(97)80173-0.Peer-Reviewed Original Research